# NCT00542451 (NCT00542451)

> Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

No report yet. It can be ordered.

- Drugs tested: paclitaxel plus trastuzumab
- Indication: node-negative HER2-positive breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00542451
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Breast Cancer; Carcinoma of the Breast
- Interventions: Paclitaxel; Trastuzumab
- Enrollment: 406
- Primary outcome: 3-year Disease Free Survival (DFS) Rate

## Indexed commentary on NCT00542451 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 49 posts on X
- 37 YouTube videos
- 21 podcast episodes
- 4 videos on X

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct00542451

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00542451", "email": "<work email>"}; the inbox owner confirms by the emailed link.